Despite tangible progress in recent years, substantial therapeutic challenges remain in multiple myeloma (MM), particularly for patients at high risk for early relapse or death and for those with advanced multi-drug resistant disease and refractoriness to currently available combination regimens. Addressing these challenges requires identification of novel classes of anti-MM agents, their incorporation into safe and more effective combination regimens, and development of efficient algorithms to select the most appropriate therapeutic options for the clinical and molecular features of individual patients at a given time during their disease. Ideally, these goals can be facilitated by preclinical identification of the "driver" molecular lesions on which different myeloma subtypes exquisitely depend, and by informative preclinical models simulating the clinical setting(s) in which trials will be conducted. Large prospective studies of patients treated uniformly with contemporary clinical regimens are essential, but there is also a major need for flexibility in studying new regimens in the future. Long-term patient follow-up and integrated annotation of clinical (safety and efficacy) and correlative (molecular, biochemical, etc) data are also critical. Novel molecular profiling techniques will likely identify more clinically and biologically discrete subsets of patients with recurrent, even if infrequent, lesions. This molecular heterogeneity, combined with the increasing numbers of candidate therapeutic targets and respective investigational agents, may pose formidable challenges for the development and implementation of personalized medicine in MM. This review discusses these challenges, as well as potential strategies to address them, with the aim of making significant improvement in the clinical outcome of patients with MM.
INTRODUCTION
During the last 10 years, several randomized controlled trials in different clinical settings of multiple myeloma (MM) have shown that regimens containing bortezomib, 1,2 thalidomide, 3-5 or lenalidomide [6] [7] [8] [9] increase the progression-free-and in many cases overall-survival of patients as compared with regimens used in the prethalidomide era. Therefore, the improved overall survival of patients with MM diagnosed between 2001 and 2006 (which does not yet fully account for the impact of lenalidomide or its combination with bortezomib on patient outcome) versus before 2000 10 can be attributed, at least in part, to these novel agents and not just to concurrent advances in supportive care, such as the use of bisphosphonates for bone disease. 11 However, the overall survival curves in the postthalidomide era contain two concerning features, namely, their lack of an identifiable plateau and their early and sometimes steep drop-off. These features respectively suggest that currently available treatment options for myeloma are unlikely to be curative for a large portion of patients, and that a substantial proportion of patients at high risk for early relapse or death do not receive maximal benefit from currently available combination regimens. It should be noted that these observations might change favorably with additional follow-up after the 2006 US Food and Drug Administration (FDA) approval of lenalidomide or after the introduction and broader use of bortezomib-lenalidomide combinations in clinical practice. Nevertheless, a conservative projection on the basis of currently available experience is that a substantial portion of high-risk patients may not receive maximal benefit even from double or triple combinations of novel agents with or without conventional agents. Thus, only a small subset of patients, including those with standard-risk features, will ever likely achieve a curative outcome.
Therefore, substantial therapeutic challenges remain. This review article discusses, on the basis of information available to date, some of the directions that may help address these challenges in the future. Emphasis is placed on the ongoing efforts to identify novel classes of anti-MM agents, incorporate them into safe and more effective combination regimens, and develop efficient algorithms to select the most effective therapeutic options that match the clinical and molecular features of individual patients at any given point in the course of their disease.
NOVEL AGENTS FOR THE TREATMENT OF MYELOMA
The major leaps in improving clinical outcome in MM over the last decade have been primarily driven by the successive introduction of new agents that not only exhibited anti-MM activity as monotherapy but also importantly demonstrated lack of cross-resistance with previously available classes of drugs. [12] [13] [14] [15] [16] [17] Following this successful blueprint, research for additional classes of novel therapeutics has continued in the MM field.
18-20 The spectrum covered by these agents is quite broad. Attempting to classify them by any individual criterion (eg, documented or hypothesized putative targets and mechanisms of action, safety and efficacy profiles in preclinical studies, current phase of clinical development) may not comprehensively reflect their heterogeneous, but often overlapping, features or accurately reflect their potential for providing clinical benefit in this disease. 21 Subsequent studies have shown that pomalidomide maintains key aspects of the mechanism of action of lenalidomide, including the dual activation of caspase 8 and caspase 9 apoptotic signaling and ability to synergize in vitro with proteasome inhibitors, such as bortezomib. 22 Phase I clinical studies of pomalidomide plus low-dose dexamethasone showed activity in patients with MM resistant to other anti-MM agents, including thalidomide, lenalidomide, and bortezomib. 17 The second-generation proteasome inhibitor carfilzomib binds irreversibly to the ␤5 subunit of the 20S proteasome (unlike the reversible binding of bortezomib or its orally bioavailable analog MLN2238/MLN9708) and has demonstrated clinical activity (primarily in bortezomib-naive or -exposed patients, but less so in those truly resistant) with a favorable safety profile and notably lower rates of peripheral neuropathy. 23, 24 Ongoing clinical studies of pomalidomide and second-generation proteasome inhibitors will determine which or how many will receive FDA approval. An intriguing question yet to be answered regarding the latest generation of IMIDs or proteasome inhibitors is whether their use in patients naive to other agents of this drug class (eg, in the upfront setting) would produce efficacy and safety results comparable or superior to those produced by the prototypic members of each class. For example, given that carfilzomib and bortezomib have the same molecular target (specifically, the ␤5 proteasome subunit) but produce different rates of peripheral neuropathy, there are intriguing questions as to the molecular basis for this different safety profile and whether carfilzomib could emerge in the future as the proteasome inhibitor of choice for patients at high risk for treatment-emergent neuropathy. Answers to such questions will have important implications for the long-term use of these agents in clinical practice and the sequence in which they may be used in subsequent treatment. Compared with currently available FDAapproved prototypes, new-generation IMIDs and proteasome inhibitors may conceptually represent only an incremental advance, but they may provide more treatment options (and potentially some safer ones), which could translate into substantial benefit over time. This may provide an important additional bridge until the point at which yet newer novel classes of drugs with greater anti-MM activity are identified.
SECOND-GENERATION PROTEASOME INHIBITORS AND NEW IMMUNOMODULATORY THALIDOMIDE DERIVATIVES

NOVEL CLASSES OF ANTI-MM AGENTS IN CLINICAL DEVELOPMENT
Another [47] [48] [49] and the alkylating agent bendamustine. 50, 51 There is also a continuously expanding constellation of novel agents that have undergone variable degrees of preclinical evaluation, but so far, their clinical development is in earlier stages. Some agents hit pathways or targets overlapping with those affected by the agents already described, but they also have additional effects (for instance, dual inhibitors of mTORC1/2 or composite mTORC1/2-phosphoinositide 3-kinase inhibitors 52 have profiles of activity distinct from classical rapamycin analogs, which hit only mTORC1). Other agents target previously credentialed pathways but at distinct molecular levels and engender differential biologic effects. For instance, the NEDD8-activating enzyme inhibitor MLN4924 targets the neddylation pathway (upstream of the 20S proteasome), triggering molecular sequelae and preclinical anti-MM activity distinct from established 20S proteasome inhibitors. 53 Other novel agents include mAbs against MM cell surface antigens (eg, CD38, CD40, CD138, CD200), growth factors (eg, anti-interleukin-6 antibody siltuximab/ CNTO 328), 54 ; Aurora kinases (eg, MLN8237 or others [60] [61] [62] ); and telomerase inhbitors (eg, imetelstat/GRN163L). Although the adverse clinical outcome in patients with MM with t(4;14) was originally attributed to overexpression and additional mutations of FGFR3, recent data suggest a major putative role for the histone methyltransfersase MM-SET 63,64 and raise the possibility that it could be a bona fide therapeutic target for this subset of MM. Other molecularly defined subsets of MM also conceivably harbor therapeutically tractable molecular lesions, but it is not yet clear which of these lesions are essential for MM cell survival in each of these subsets.
Therapeutics 
IMPORTANCE OF INFORMATIVE PRECLINICAL MODELS
Having a plethora of investigational agents under preclinical or clinical evaluation does not necessarily translate into clinical progress. Many of the most promising investigational agents for MM are variants of existing FDA-approved therapies for this disease, whereas other novel agents that mechanistically depart from the well-established path of thalidomide derivatives and proteasome inhibitors have not yet demonstrated potent single-agent activity in heavily pretreated patients with MM. In fact, a broader concern is that preclinical results, even highly promising ones, translate only infrequently into clinical success. Indeed, fewer than 10% of agents entering phase I testing in any cancer receive FDA approval for any indication. 79 It may therefore be sobering but prudent to recognize the possibility that more preclinical and clinical work will be needed before new classes of anti-MM monotherapies become widely available. For some investigational agents, alternative dose, route of administration, and scheduling might perhaps reveal improved single-agent anti-MM efficacy. For all investigational agents, it is otherwise important to stringently consider at a preclinical level how critical the corresponding targets are for MM cell biology and which patient subsets would have the highest likelihood of benefit from such therapeutic intervention. Molecular targets with differential expression in MM (v normal tissues) may be completely unattractive for therapeutic interventions if they are functionally redundant for tumor cell viability. Functional studies identifying the "driver" molecular lesions on which tumor cells exclusively depend should be an elemental criterion in selecting targets for therapeutic testing. To remain informative, preclinical models should be finetuned to optimize their relevance to the clinical settings in which trials will be conducted. Tumor-microenvironment interactions can confer drug resistance to diverse drug classes and may contribute to the suboptimal clinical translation of otherwise exciting preclinical results. Therefore,invivostudies(bothforxenograftsandgeneticmodels)should ideally be orthotopic (ie, reflect anatomic distribution of lesions in patients with MM). 80 Notably, recent studies have shown that nonmalignant accessory cells of the tumor microenvironment can render MM cells more sensitive to certain classes of therapeutics, which presumably target key pathways triggered in tumor cells by their milieu. 80 In vitro screening for anti-MM agents should therefore be performed not against MM cells cultured in isolation but rather in the presence of nonmalignant accessory cells. The risk is that otherwise, agents that are subject to this previously underappreciated microenvironment-dependent synthetic lethality may be filtered out of preclinical and clinical pipelines, depriving the field of some potentially useful candidate therapeutics. 80 Clinical testing of a novel agent in unselected patient populations may dilute any efficacy signal (even a potent one), if it is restricted to relatively infrequent subsets of patients with MM . Identification of candidate biomarkers of response or resistance should be pursued, when feasible, as early as possible in preclinical development through studies across different subtypes, using large cell-line panels (not withstanding under-representation of cases of hyperdiploid MM) and/or primary MM tumor cells. Candidate markers derived from such exploratory studies should not be used to restrict or exclude patient enrollment in ensuing clinical trials; rather, such studies should help enrich them for patient subsets with the highest likelihood of response, allowing for prospective validation by comparisons of outcome in patients with versus without the markers of interest.
Novel agents (alone or in combination) are expected to be explored not only in induction regimens but also to augment the depth of response to conditioning regimens, for consolidation as well as maintenance. Since early reports of positive efficacy data for single-agent lenalidomide as maintenance after ASCT, 8,9 studies of maintenance use of proteasome inhibitors (alone or in combination with lenalidomide) and other agents have been eagerly awaited. Alternative schedules and even route of administration (eg, growing experience with subcutaneous administration of bortezomib 81 ) could conceivably facilitate such studies. 86 On the basis of encouraging early clinical experience with newer generation IMIDs (eg, pomalidomide) and proteasome inhibitors (eg, carfilzomib), it is anticipated that these agents will also be incorporated in similar combinations and assume the positions of their corresponding first-or second-in-class agents. This direction is also supported by preclinical evidence, 89, 90 which shows that the original concept of combining proteasome inhibitors with thalidomide derivatives 22 to achieve enhanced direct anti-MM effects not only applies to bortezomib and lenalidomide but also represents an overall class effect.
ROLE OF COMBINATION REGIMENS IN THE FUTURE OF MM TREATMENT
Other notable combinations integrate agents that have not been approved by the FDA for MM treatment but have shown encouraging rates and depth of response in combination with existing anti-MM regimens. Examples include the previously mentioned combinations of HDAC inhibitors with bortezomib 28,31,34,91 or lenalidomide and dexamethasone, 92 elotuzumab plus lenalidomide and dexamethasone, 93 and hsp90 inhibitors plus bortezomib. 37 The pleiotropic effects of HDAC and hsp90 inhibitors on multiple proteins critical for oncogenesis and drug resistance conceivably account for their roles as sensitizers to other anti-MM agents. HDAC inhibition suppresses expression of diverse oncogenic transcripts, 25 blunts compensatory transcriptional responses mounted by MM cells attempting to escape the proapoptotic effect of bortezomib, 25 and leads to hyperacetylation and decreased function of hsp90, hypoxia-inducible factor 1-alpha, and other oncogenic proteins. Consistent with these observations, combinations of vorinostat (also known as suberoylanilide hydroxamic acid) with bortezomib have shown enhanced preclinical anti-MM activity. 25 This has been subsequently confirmed with other HDAC inhibitors as well. 33 HDAC inhibition also affects the aggresome, an alternative pathway for intracellular protein degradation. 33, 94 The transcriptional and protein homeostasis effects of HDAC inhibitors could conceivably cooperate to enhance the anti-MM activity of bortezomib, including clinical responses even in bortezomib-refractory patients.
28, 91 The combination of elotuzumab with lenalidomide was made based on the notion that the immunostimulatory effect of lenalidomide would enhance the antibodydependent cellular cytotoxicity triggered by elotuzumab.
The emergence of several potent triplet or quadruplet anti-MM combinations is reminiscent of successes with similarly complex regimens for other hematologic malignancies (eg, Hodgkin's lymphoma, diffuse large B-cell lymphoma). Will IMID/proteasome inhibitor regimens such as RVD (with Ͼ 90%, Ͼ 70%, and Ͼ 50% rates of partial, very good partial, and complete or near-complete responses, respectively, in newly diagnosed MM) improve the long-term outcome of patients with high-risk features? Will RVD-by itself or in combination with another agent (potentially an HDAC inhibitor, the hsp90 inhibitor perifosine, or elotuzumab)-provide a DNA-damaging chemotherapy-free induction regimen that will improve clinical outcome with ASCT? Are there subsets of patients with MM for whom RVD-based therapy could provide comparable outcome with or without ASCT? Conversely, are there patient subgroups for whom the rates and depth of response to RVD would be comparable to those with treatment with only a bortezomib-or lenalidomide-based approach; if so, could these patients benefit from the sequential or alternative use of drugs of these classes rather than the deployment of all possible classes of active anti-MM agents early on in the course of disease? Studies such as the IFM-DFCI (French Francophone Myeloma Intergroup-DanaFarber Cancer Institute) study of RVD with versus without ASCT (NCT01208662) or the trial of bortezomib and dexamethasone with versus without lenalidomide (NCT00522392) and other future trials will help address these questions, in terms of not only rates and depth of response but also safety profile, progression-free survival, and ideally overall survival. With regard to the latter end point, the need for long-term follow-up and the potential confounding effect of heterogeneous salvage therapy across treatment arms are recognized; they pose fundamental clinical research challenges, although to date, in comparative studies of novel therapies, concordance between progression-free and overall survival has been consistently observed.
Delivering the appropriate overall intensity of treatment to those patients who need it most and sparing other patients, particularly elderly patients or those with other comorbid conditions, from a potentially increased risk of adverse effects and higher cost will require prospective identification of those patients who have a high probability of major clinical response with single-agent or doublet treatment compared with more complex combination regimens. These questions lie at the heart of another major frontier for translational research in MM, namely, the concept of personalized medicine.
PERSONALIZED TREATMENT IN MM: ARE WE THERE YET?
Future Directions
The clinical and biologic heterogeneity of MM leaves little room for rigidly uniform "one-size-fits-all" therapeutic approaches for all patients. Administering the right treatment to the right patients at the right point during the course of their disease is of paramount importance, but this is not a recently discovered concept in MM or beyond. In fact, the International Staging System, widely available cytogenetic techniques (metaphase karyotype, fluorescent in situ hybridization), and more recently the mSMART (Mayo Stratification for Myeloma and Risk-Adapted Therapy) algorithm-and University of Arkansas for Medical Sciences gene expression-based high-risk scores are examples of platforms intended to eventually facilitate the individualized management of MM. The current resurgence of the question of personalized treatment in MM reflects the recent expansion of the anti-MM therapeutic armamentarium, which has altered the significance of some classical prognostic markers, 2,95 and concurrent advances in the molecular characterization of MM. 96 Both of these developments are key prerequisites for more efficient individualized therapeutic algorithms in a neoplasm as complex and heterogeneous as MM.
Indeed, in recent years, long-standing experience with more established metaphase karyotype and fluorescent in situ hybridization data 97 has been complemented by comprehensive data on gene expression profiles, 98-105 chromosomal amplifications or deletions, 104-106 DNA mutations, 107-109 and methylation profiling 105 on CD138ϩ MM tumor cells from different MM clinical settings (newly diagnosed, relapsed, and relapsed refractory patients), including cohorts of uniformly treated patients. [98] [99] [100] [101] [102] [103] [104] [105] Notwithstanding some different results across various groups (likely resulting from different analytic approaches), a consensus has emerged on identifying certain key MM subsets on the basis of their underlying primary genetic events (eg, hyperdiploid v nonhyperdiploid MM, with several subclassifications of the latter, depending on the exact nature of the underlying primary immunoglobulin gene translocation). These subsets may also include secondary molecular events 96 (eg, deletions of chromosomes 13q, 17p, or 1p; amplifications of chromosome 1q; secondary translocations of the MYC locus; and diverse mutations of NRAS, KRAS, or p53, for example (which are present in the overwhelming majority of cases of far-advanced MM/plasma cell leukemia). The secondary genetic events are not considered initiating events in myelomagenesis but can influence biologic behavior and clinical outcome, especially in 1q amplification, 100 ,110 17p deletion, and p53 mutation.
95,111
However, the ultimate objective of individualized management of MM is not to merely define additional subsets of patients with MM and simply catalogue their respective molecular lesions or differential prognoses. The molecular profiling studies described here have made progress in all of these directions, but this is arguably only a first step. The ultimate goal is to provide patients of different MM subtypes with treatment options that will lead-compared with decisions made based on more conventional risk-stratification schemes-to improved progression-free and, ideally, overall survival as well as safety profiles and quality of life while hopefully containing the overall cost of care. Implementing such goals is not easy, as attested by experience in other diseases (eg, adult acute myelogenous leukemia) in which molecular markers for risk-adaptive treatment algorithms did not instantly lead to significantly improved clinical outcomes. Instead, identifying the most appropriate targeted therapies for each patient subset is critical. The intermediate steps toward these goals are to identify for patients of each MM subset which currently available treatments (monotherapies or combinations) have the most potent and durable clinical responses; which molecular targets are the critical drivers of the biologic and clinical behavior of that patient subgroup and which investigational agents can safely and efficiently affect such targets, if established agents do not; conversely, which available therapies have poor clinical outcome and should therefore be avoided; whether dose or schedule modifications or even avoidance of a given treatment are necessary because of high risk for adverse effects; and which therapies may be particularly active for patients with MM with higher-risk features (eg, International Staging System stage III disease 112 or 17p deletion) who are not receiving maximal benefit from the current novel therapies and/or combinations. An important barrier in implementing those intermediate steps is the fact that many of the molecular lesions that are characteristic of the different subtypes of MM are not currently addressed by specific targeted therapies, either because they represent deletions of tumor suppressor genes or because they are amplifications (eg, c-MAF, MYC) or mutations (eg, RAS) of oncogenes for which no specific targeted therapies are currently available in advanced stages of clinical development. More emphasis should perhapsbeplacedontherapiesthatcreateasyntheticlethalityinthecontextof these currently intractable targets 113 as well as on therapeutic targeting of RNA expression/function (eg, shRNA or siRNA constructs).
Enacting these intermediate steps will also require patient and comprehensive implementation at both clinical and laboratory research levels. Large prospective studies of patients treated uniformly with contemporary clinical regimens are essential, though the need for flexibility in studying new regimens in the future is recognized. Longterm patient follow-up and detailed annotation of clinical outcome is critically important and should not be restricted to tumor burden, time to and duration of response, or progression-free and overall survival. Information on certain specific clinical pictures (eg, aggressive extramedullary relapses or patient profiles evolving after therapy into monoclonal gammopathy of undetermined significance-like molecular profiles) is important to understand the molecular characteristics underlying these settings. Information should be collected on postrelapse salvage therapies, if these are not assigned to all patients uniformly or are not subject to new randomization within a given study. Baseline and serial correlative studies may include, but not be restricted to, integrated multidimensional molecular annotation (conventional cytogenetic data and results from gene expression profiles, mutation analyses, DNA copy number analyses, methylation profiles, and so on). In addition, better tools to monitor treatment responses both in and outside bone marrow will be important to avoid under-or overtreating patients. These tools include imaging studies (eg, positron emission tomography 114 ), multiparameter flow cytometry, 115 and real-time quantitative polymerase chain reaction for minimal residual disease evaluation, which have provided informative data and also merit additional prospective evaluation. Collection and storage of samples for correlative studies should also allow for future testing with new and ideally more sensitive and specific molecular techniques that may not be available at this moment. Molecular testing should focus not only on the tumor and putative biomarkers of its response to treatment but also on patients' normal cells to evaluate potential predisposition to adverse effects (as illustrated in the study by Broyl et al 102 ), including both short-term adverse effects and longterm complications of treatment or of the disease process itself. Such safety-oriented biomarkers could help modify the dose/schedule of individual agents or determine which partner drugs or sequences of administration are selected for combinations.
Correlative studies should ideally focus on biomarkers credentialed by stringent functional preclinical vetting before attempts for clinical validation. The specific method for evaluation of a candidate biomarker should be carefully optimized for the type of specimens that will be tested as well as in terms of sensitivity, specificity, and cost effectiveness. Importantly, the method of study of a given biomarker should be easy to implement beyond the walls of highly specialized tertiary care centers. MM cells in a given patient may exhibit substantial molecular heterogeneity and drug responsiveness, with the emerging concept of cancer stem cells being a prime example. Developing tests that are not confounded by such heterogeneity will be a major frontier of research in the years to come.
Many of these directions will not be easy to implement in the near future, and individualized treatment efforts in MM will continue to face major challenges, similar in nature to those in other disciplines. 116 The numbers of clinically and biologically discrete subgroups of patients with MM will increase as more sensitive molecular techniques identify additional recurrent, even if infrequent, lesions. The overall complexity of the classifications and treatment algorithms will rise exponentially with identification of more candidate targets and respective investigational agents. Numerous combination regimens are already available, but correlative studies and mature follow-up of uniformly treated patients with MM (who now tend to live longer as a result of multiple lines of effective therapy) are often completed only after next-generation regimens with higher response rates have already been introduced. This partly reflects overall progress in the field, but it also calls for innovative clinical trial designs that will prevent biomarker discovery and validation efforts from becoming rapidly outdated because of potential shifts in clinical practice.
Another inherent challenge in MM and other cancers is that individualized management for the increasing number of ever smaller molecularly defined subsets may seem philosophically at odds with the perceived concept that evidence-based medicine should be rooted in average or median estimates of clinical outcome in large, yet heterogeneous, patient populations. 117 The temptation to abandon the basic principles of randomized controlled clinical investigation should be avoided in the MM field. We should instead attempt to strike a balance, namely, continue to conduct large randomized studies (particularly for active agents and combinations with multitargeted effects that transcend multiple disease subtypes) and long-term follow-up but also pursue careful studies of smaller patient subgroups (especially those associated with dismal outcome) harboring critical driver molecular lesions and, if available, of highly selective investigational therapies against those targets, informed by innovative bench research. 118 The degree to which this balance is achieved in the MM field will have a major impact on the direction of clinical practice in MM for the foreseeable future. 
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